Allarity Therapeutics (ALLR)
1.61
0.00 (0.00%)
Upcoming Events
Latest Headlines
Form 8-K Allarity Therapeutics, For: May 27
June 2, 2026 5:11 PM - SEC Filing
Allarity Therapeutics (ALLR) Misses Q1 EPS by 17c
May 18, 2026 6:46 AM - StreetInsider
Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers
May 15, 2026 4:30 PM - StreetInsider
Form 10-Q Allarity Therapeutics, For: Mar 31
May 15, 2026 4:06 PM - SEC Filing
Form 4 Allarity Therapeutics, For: Jan 28 Filed by: Jensen Thomas
May 14, 2026 11:49 AM - SEC Filing
Form 4 Allarity Therapeutics, For: Jan 28 Filed by: Hoeiland Jesper
May 11, 2026 3:22 PM - SEC Filing
Form 3 Allarity Therapeutics, For: Jun 10 Filed by: Hoeiland Jesper
May 11, 2026 3:21 PM - SEC Filing
Form 8-K Allarity Therapeutics, For: May 08
May 8, 2026 5:20 PM - SEC Filing
Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm
May 8, 2026 8:45 AM - Globe NewsWire
Form 4 Allarity Therapeutics, For: Jan 28 Filed by: McLaughlin Gerald W.
May 7, 2026 6:25 PM - SEC Filing
Form 8-K Allarity Therapeutics, For: May 05
May 6, 2026 8:06 AM - SEC Filing
Allarity begins Phase 3 manufacturing for stenoparib cancer drug
May 5, 2026 8:00 AM - StreetInsider
Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign
May 5, 2026 8:00 AM - Globe NewsWire
Form ARS Allarity Therapeutics, For: Dec 31
April 30, 2026 5:31 PM - SEC Filing
Form DEFA14A Allarity Therapeutics,
April 30, 2026 5:30 PM - SEC Filing
Form DEF 14A Allarity Therapeutics, For: Jun 26
April 30, 2026 4:16 PM - SEC Filing
Form 4/A Allarity Therapeutics, For: Jan 28 Filed by: Graff Jeremy R.
April 30, 2026 3:38 PM - SEC Filing
Form 4 Allarity Therapeutics, For: Jan 28 Filed by: Ervin Jeffrey S
April 30, 2026 3:38 PM - SEC Filing
Form 8-K Allarity Therapeutics, For: Apr 27
April 28, 2026 8:04 AM - SEC Filing
Allarity receives patent allowance for stenoparib diagnostic test
April 27, 2026 8:00 AM - StreetInsider
Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office
April 27, 2026 8:00 AM - Globe NewsWire
Form 424B3 Allarity Therapeutics,
April 27, 2026 7:45 AM - SEC Filing
Form EFFECT Allarity Therapeutics,
April 27, 2026 6:04 AM - SEC Filing
Form S-3/A Allarity Therapeutics,
April 24, 2026 1:02 PM - SEC Filing
Form 8-K Allarity Therapeutics, For: Apr 21
April 22, 2026 8:16 AM - SEC Filing
Allarity presents cancer drug data at AACR conference
April 21, 2026 8:02 AM - StreetInsider
Allarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib’s Potential in Colorectal Cancer as well as New Predictive Data Linking DRP® and Overall Survival in Ovarian Cancer
April 21, 2026 8:01 AM - Globe NewsWire
Form PRE 14A Allarity Therapeutics, For: Apr 10
April 10, 2026 5:19 PM - SEC Filing
Form 8-K Allarity Therapeutics, For: Mar 31
April 1, 2026 8:55 AM - SEC Filing
Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress
March 31, 2026 8:01 AM - Globe NewsWire
Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress
March 31, 2026 8:00 AM - StreetInsider
Form 10-K Allarity Therapeutics, For: Dec 31
March 30, 2026 5:31 PM - SEC Filing
Full Article List
